spebrutinib
E1549337
UNEXPLORED
Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| spebrutinib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22690614 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: spebrutinib Context triple: [BTK, inhibitedBy, spebrutinib]
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: spebrutinib Target entity description: Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.